अभिवृद्धी न्यूट्रावेद आयपीओ जीएमपी, सदस्यता आणि वाटप स्थिती आज
अभिवृद्धी न्यूट्रावेद is a SME IPO with a price band of Rs 122.00 to Rs 129.00 that listed on 04 Feb 2026 at a listing gain of +48.06%. Track its full GMP history, subscription data and listing details here.
- प्राइस बँड
- ₹122.00 - ₹129.00
- लॉट आकार
- 1,000 शेअर्स
- बोली बंद झाली
- 30 Jan 2026
- लिस्टिंग तारीख
- 04 Feb 2026
आयपीओ माहिती पूर्ण करा
| सध्याचे जीएमपी | ₹62 |
|---|---|
| अंदाजे लिस्टिंग फायदा | +48.06% |
| प्राइस बँड | ₹122.00 - ₹129.00 |
| इश्यू प्राईस | Approx ₹129.00 Crores |
| लिस्टिंग किंमत | ₹191.00 |
| लॉट आकार | 1,000 शेअर्स |
| समस्येचा प्रकार | एसएमई |
| रजिस्ट्रार | टीबीए |
| विनिमय | NSE, BSE |
| किरकोळ कोटा | टीबीए |
| एकूण सबस्क्रिप्शन | टीबीए |
| लिस्टिंग तारीख | 04 Feb 2026 |
| किमान गुंतवणूक | ₹2,58,000 |
अभिवृद्धी न्यूट्रावेद आयपीओ समान आयपीओशी तुलना करा
आयपीओ स्नॅपशॉट आणि गुंतवणूकदारांनी घेतलेले निष्कर्ष
त्याच्या किंमत बँडच्या वरच्या टोकाला, अभिवृद्धी न्यूट्रावेद ची किंमत प्रति शेअर ₹129 आहे. 1,000 शेअर्सच्या किमान लॉट आकारासह, एका लॉटसाठी अर्ज करणार् या किरकोळ गुंतवणूकदारास या SME अंकात भाग घेण्यासाठी अंदाजे ₹2,58,000 आवश्यक आहे.
अभिवृद्धी न्यूट्रावेद साठी नवीनतम रेकॉर्ड केलेला ग्रे मार्केट प्रीमियम ₹62 आहे, ज्याचा अर्थ असा आहे की लिस्टिंग जर ते लिस्टिंग पर्यंत टिकले तर इश्यू किंमतीपेक्षा अंदाजे 48.06% फायदा होईल. हे त्याच्या पूर्वीच्या नोंदविलेल्या पातळीपेक्षा ₹53 वर आहे. जीएमपी गॅरंटीड परिणामाऐवजी अनौपचारिक ग्रे-मार्केट भावना प्रतिबिंबित करते, आणि लिस्टिंग च्या दिवसापर्यंत कोणत्याही वेळी बदलू शकते.
बीएसई / एनएसईच्या समर्पित एसएमई प्लॅटफॉर्मवर एसएमई आयपीओ सूचीबद्ध आहेत. त्यामध्ये सामान्यत: लहान इश्यू आकार आणि मेनबोर्ड इश्यूपेक्षा जास्त प्रति-लॉट गुंतवणूकीचा समावेश असतो, तुलनेने कमी संस्थात्मक सहभागासह.
आयपीओ रोडमॅप एका दृष्टीक्षेपात
दैनंदिन जीएमपी स्थिती
| तारीख | जीएमपी | बदल | लाभ |
|---|---|---|---|
| 04 Feb 2026 | ₹69.00 | +₹53.00 | 53.49% |
| 03 Feb 2026 | ₹16.00 | +₹10.00 | 12.40% |
| 02 Feb 2026 | ₹6.00 | - | 4.65% |
अनुप्रयोग आकार ब्रेकडाउन
| श्रेणी | लॉट | शेअर्स | रक्कम |
|---|---|---|---|
| किरकोळ किमान | 2 लॉट | 2,000 | ₹2,58,000 |
| किरकोळ कमाल | 2 लॉट | 2,000 | ₹2,58,000 |
| एस-एचएनआय किमान | 3 लॉट | 3,000 | ₹3,87,000 |
| एस-एचएनआय कमाल | 7 लॉट | 7,000 | ₹9,03,000 |
| बी-एचएनआय किमान | 8 लॉट | 8,000 | ₹10,32,000 |
इश्यूचे मुद्दे आणि अधिकृत कागदपत्रे
Accretion Nutraveda IPO – Key Details
| IPO Open Date | January 27, 2026 |
| IPO Close Date | January 30, 2026 |
| Face Value | ₹10 per Equity Share |
| Price Band | ₹122 – ₹129 per Share |
| Issue Size | Approx ₹24.77 Crores |
| Fresh Issue | Approx ₹24.77 Crores |
| Issue Type | Book Build Issue |
| IPO Listing | BSE SME |
Accretion Nutraveda IPO – Market Lot Details
| Application | Lot Size | Shares | Amount (₹) |
|---|---|---|---|
| Retail Minimum | 2 | 2,000 | 2,58,000 |
| Retail Maximum | 2 | 2,000 | 2,58,000 |
| S‑HNI Minimum | 3 | 3,000 | 3,87,000 |
| S‑HNI Maximum | 7 | 7,000 | 9,03,000 |
| B‑HNI Minimum | 8 | 8,000 | 10,32,000 |
Accretion Nutraveda IPO – Reservation Details
| Investor Category | Shares Offered | Percentage (%) |
|---|---|---|
| Anchor Investors | – | – |
| QIB (Ex‑Anchor) | 9,08,000 | 47.29% |
| NII | 2,76,000 | 14.37% |
| Retail | 6,40,000 | 33.33% |
Accretion Nutraveda IPO – Anchor Investors
| Anchor Bidding Date | January 2026 |
| Anchor Investors List | – |
| Shares Offered to Anchor Investors | – |
| Anchor Size | – |
| Lock‑in Period (50% – 30 Days) | 2026 |
| Lock‑in Period (50% – 90 Days) | 2026 |
Accretion Nutraveda IPO – Important Dates
| IPO Open Date | January 27, 2026 |
| IPO Close Date | January 30, 2026 |
| Basis of Allotment | February 2, 2026 |
| Refunds Initiation | February 3, 2026 |
| Credit to Demat Account | February 3, 2026 |
| IPO Listing Date | February 4, 2026 |
| IPO Bidding Cut‑off Time | January 30, 2026 – 5:00 PM |
Accretion Nutraveda IPO – Promoters & Holding Pattern
Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel
| Particulars | Shares | Shareholding (%) |
|---|---|---|
| Promoter Holding (Pre‑Issue) | 53,20,000 | 100.00% |
| Promoter Holding (Post‑Issue) | 72,40,000 | 73.48% |
Accretion Nutraveda IPO – Objects of the Issue & Utilisation of Proceeds
| Purpose | Amount (₹ Cr) |
|---|---|
| Purchase of machineries for automation in existing manufacturing unit | 4.22 |
| Purchase of machineries for new manufacturing setup | 8.03 |
| Funding working capital requirements of the company | 5.50 |
| General Corporate Purpose | – |
About Accretion Nutraveda IPO
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.
The company serves its customers in India as well as in international countries like Sri Lanka, Singapore, and the USA. The firm blends Ayurvedic and science to offer treatments for various areas, like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness. The company runs a 10,763 sq. ft. manufacturing facility situated in Gujarat. Its unit includes modern infrastructure and quality control systems.
Accretion Nutraveda IPO – Company Financial Report
| Period Ended | Revenue (₹ Cr) | Expense (₹ Cr) | PAT (₹ Cr) | Assets (₹ Cr) |
|---|---|---|---|---|
| FY 2023 | 3.07 | 2.78 | 0.28 | 4.06 |
| FY 2024 | 5.20 | 4.28 | 0.82 | 4.64 |
| FY 2025 | 16.06 | 12.87 | 2.61 | 10.86 |
Accretion Nutraveda IPO – Valuation (FY2025)
| KPI | Values |
|---|---|
| ROE | 81.22% |
| ROCE | 36.98% |
| EBITDA Margin | 22.79% |
| PAT Margin | 16.33% |
| Debt to Equity Ratio | – |
| Earning Per Share (EPS) | ₹7.19 (Basic) |
| Price / Earnings (P/E) | N/A |
| Return on Net Worth (RoNW) | 48.85% |
| Net Asset Value (NAV) | ₹14.72 |
Accretion Nutraveda IPO – Peer Group Comparison
| Company | EPS (₹) | P/E Ratio | RoNW (%) | NAV (₹) | Income (₹ Cr) |
|---|---|---|---|---|---|
| Walpar Nutritions Ltd. | 1.80 | 23.94 | 11.27% | 13.65 | 60.26 |
| Influx Healthtech Limited | 7.31 | 25.93 | 36.72% | 5.31 | 104.99 |
IPO Lead Managers aka Merchant Bankers
- Sobhagya Capital Options Pvt. Ltd.
अभिवृद्धी न्यूट्रावेद आयपीओ वारंवार विचारले जाणारे प्रश्न
Comments
Share a useful question or insight about अभिवृद्धी न्यूट्रावेद.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Loading comments...